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DOI 10.1016/j.ccr.2009.12.042SUMMARYMany different molecular mechanisms have been associated with PML-RARa-dependent transformation of
hematopoietic progenitors. Here, we identified high confidence PML-RARa binding sites in an acute promye-
locytic leukemia (APL) cell line and in two APL primary blasts. We found colocalization of PML-RARa with
RXR to the vast majority of these binding regions. Genome-wide epigenetic studies revealed that treatment
with pharmacological doses of all-trans retinoic acid induces changes in H3 acetylation, but not H3K27me3,
H3K9me3, or DNA methylation at the PML-RARa/RXR binding sites or at nearby target genes. Our results
suggest that PML-RARa/RXR functions as a local chromatin modulator and that specific recruitment of
histone deacetylase activities to genes important for hematopoietic differentiation, RAR signaling, and epige-
netic control is crucial to its transforming potential.INTRODUCTION
Acute promyelocytic leukemia (APL) is a distinct subtype of acute
myeloid leukemia characterized by severe bleeding tendency
and a fatal course of only few weeks’ duration (Wang and
Chen, 2008). It is mostly triggered by the chromosomal transloca-
tion of the PML gene on chromosome 15 and the retinoic acid
receptor a (RARa) on chromosome 17 that results in expression
of the PML-RARa oncofusion gene in hematopoietic myeloid
cells (de The et al., 1990; Kakizuka et al., 1991). The PML-RARa
oncofusion protein acts as a transcriptional repressor that inter-
feres with gene expression programs involved in differentiation,
apoptosis, and self-renewal (Sell, 2005).
At the molecular level, PML-RARa behaves as an altered RAR.
In absence of all-trans retinoic acid (ATRA), RARa interacts with
RXR, itself a nuclear receptor, and binds to DNA. In contrast,
PML-RARa has been reported to function by oligomerizationSignificance
Since its discovery in 1990, PML-RARa has been one of the m
understanding epigenetic repression during oncogenesis. Thr
for PML-RARa function, including homodimerization, oligomer
and recruitment of a wide spectrum of epigenetic enzymes bas
of the RARb gene. In this study we provide genome-wide ana
receptor RXR, and epigenetic changes associated with ATR
ex vivo patient blasts. Our results show that alterations of H3
RXR complex.
Cwithout RXR (Minucci et al., 2000) or to require RXR in conjunc-
tion with oligomerization (Kamashev et al., 2004; Perez et al.,
1993). The normal RARa/RXR heterodimer recruits corepressor
complexes and represses transcription of its target genes.
A conformational change caused by binding of ATRA triggers
the dissociation of the corepressors and promotes the recruit-
ment of coactivators. In contrast, PML-RARa acts as a constitu-
tive repressor that is insensitive to physiological concentrations
of ATRA (Licht, 2006; Kwok et al., 2006; Sternsdorf et al.,
2006). Under physiological concentrations of ATRA, PML-
RARa complexes have been reported to bind RXR (Perez
et al., 1993), which may be essential for its oncogenic potential
as it facilitates binding to widely spaced direct repeats (DRs)
(Perez et al., 1993; Kamashev et al., 2004) and has recently
been shown to be a critical determinant for the transforming
potential of PML-RARa complexes (Zeisig et al., 2007; Zhu
et al., 2007).ost intensely investigated translocation fusion proteins for
oughout the years many mechanisms have been proposed
ization, interaction with RXR, expanded DNA binding affinity,
ed on studying a few genomic regions, mostly the promoter
lyses of PML-RARa binding, colocalization with the nuclear
A-mediated PML-RARa degradation both in cell lines and
acetylation are intimately intertwined with the PML-RARa/
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PML-RARa-Associated Chromatin AlterationsTo overcome the transforming potential of PML-RARa, human
APL patients are treated during the early phase of the disease
with pharmacological doses of ATRA (Di Croce, 2005; Licht,
2006). This treatment has been shown to degrade PML-RARa
(Raelson et al., 1996) and suggested to dissociate various epige-
netic enzymes from chromatin, such as histone deacetylases
(HDACs) (Lin et al., 1998; Grignani et al., 1998), DNMTs (Di Croce
et al., 2002), MBDs (Villa et al., 2006; Morey et al., 2008), and
histone methyltransferases (Carbone et al., 2006; Villa et al.,
2007). Loss of these proteins has been suggested to severely
remodel the repressive chromatin environment at PML-RARa
binding sites, creating a more accessible chromatin structure.
Unfortunately, until now the majority of these epigenetic changes
have only been reported for a small region surrounding the
promoter of the RARb gene due to the lack of other high confi-
dence genomic binding sites. Thus far, the identification of addi-
tional PML-RARa binding sites has been restricted to one chro-
matin immunoprecipitation (ChIP)-chip study in which PML-
RARawas overexpressed in 6 days 5-aza-dC-treated U937 cells
(Hoemme et al., 2008), thus unlikely reflecting the canonical
disease. Similarly, only one study using CpG island arrays ad-
dressed large-scale epigenetic effects associated with ATRA
treatment (Nouzova et al., 2004).
In the present study we used ChIP-seq to identify PML-RARa
binding sites in the leukemic cell line NB4 and in blasts from
two patients with newly diagnosed APL. In addition, we exam-
ined ATRA-induced genome-wide epigenetic alterations. Our
results support a model in which recruitment of PML-RARa
in conjunction with RXR and HDACs is crucial for oncogenic
transformation.
RESULTS
Identification of PML-RARa Binding Sites in NB4
Leukemic Cells
To identify targets of the PML-RARa oncofusion protein, ChIP
followed by deep sequencing (ChIP-seq) was performed using
specific antibodies against PML and RARa in the PML-RARa-ex-
pressing leukemic cell line NB4 (Lanotte et al., 1991); in addition,
total genomic DNA was sequenced to obtain a reference input
profile. Overlapping tags were joined into peaks and displayed
as tag-density files in the University of California Santa Cruz
browser (http://genome.ucsc.edu/). The classical target RARb
shows enrichments of both PML and RARa tags over a narrow
range at the promoter region (Figure 1A, top left). PML and
RARa peaks were also detected at regions that have been previ-
ously described as potential PML-RARa targets, such as TGM2,
ID1, SPI1, and microRNA-223 (Table S1 and Figure S1A, avail-
able online) and numerous targets for which no PML-RARa
binding has been described before, such as for the hematopoi-
etic regulators GFI1 and RUNX1 and the RARa gene (Figure 1A).
These results suggest that, apart from regulating important
factors involved in hematopoietic differentiation, PML-RARa
influences retinoic acid signaling through regulation of RARa
and RARb expression. We used MACS (Zhang et al., 2008) at
a false discovery rate of 106 to identify all PML and RARa
binding regions and counted the number of PML and RARa
tags within these regions. For each binding region we calculated
the relative tag density, i.e., density at one region divided by174 Cancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc.average density at all regions. Regression curve analysis
(Figure 1B) revealed a set of 2722 genomic regions at a cut off
of 0.00012 (>14 tags/kb) to which both PML and RARa bind
with high confidence (Table S2), while no high confidence
PML- or RARa-only binding sites were found. As wild-type
PML is expected to colocalize with RARa in APL cells (Dyck
et al., 1994; Koken et al., 1994; Weis et al., 1994), these findings
suggest that the 2722 high-confidence PML and RARa binding
sites represent bona fide PML-RARa targets.
PML-RARa Colocalizes with the Nuclear Receptor RXR
Although PML-RARa has been reported to bind DNA as a homo-
dimer or oligomer (Kamashev et al., 2004; Minucci et al., 2000;
Perez et al., 1993), more recent findings indicate that RXR is
present within a functional PML-RARa complex (Zeisig et al.,
2007; Zhu et al., 2007). To investigate whether PML-RARa and
RXR colocalize at a genome-wide level we performed ChIP-
seq using a specific RXR antibody. As for PML and RARa, we
detect enrichments of RXR tags at the RARb, RARa, RUNX1,
and GFI1 and at the previously described genomic binding
regions (Figure 1A and Figure S1A). Including the RXR data in
our regression analysis revealed that the vast majority of PML-
RARa peaks contain high densities of RXR tags, indicating
a highly significant overlap between PML-RARa and RXR
binding (Figure 1B). Partitioning our 2722 binding sites according
to RXR tag density revealed that tag densities of PML, RARa, and
RXR closely correlate, indicative of stoichiometric binding
(Figure 1C). To further validate the colocalization of PML,
RARa, and RXR we performed re-ChIP experiments to confirm
binding of PML and RARa to the same locus (Figures S1B and
S1C). In addition, we validated occupancy of PML, RARa, and
RXR at 13 randomly selected regions identified in our ChIP-
sequencing approach in comparison to a control region within
the MYOGLOBIN gene (Figure S1D).
The distribution of all 2722 binding sites (Table S2) shows that
PML-RARa/RXR peaks have statistical significant enrichment
toward promoter regions as compared to the distribution of
genomic DNA (19% for PML-RARa and 5% for genomic DNA)
and a decrease (13% for PML-RARa and 31% for genomic
DNA) toward distant regions (Figure 1D).
PML-RARa/RXR Binding Regions Comprise a Wide
Variety of DR Response Elements
In vitro evidence suggests that the PML-RARa-containing
complexes have gained an expanded DNA binding capacity
away from DR5, DR2, and DR1 motifs toward more widely
spaced DRs (Kamashev et al., 2004). To examine whether this
gain of function is represented in our in vivo data, we interrogated
the binding site sequences for overrepresentation of DR motifs
with different spacing (between 0 and 13) and architecture
(direct, inverted, or everted repeat) (Figure 2A). Indeed, we find
all possible combinations of two AGGTCA half sites (Figure 2B).
While a DR1–5 motif is detected within the majority of the binding
sites (58.1%), a large number only contains DR motifs with
altered spacing and/or architecture: 21.9% contain only a DR0
or DR6–13 motif and 10.0% contain only an ER or IR motif.
Comparison with a similar analysis for RARa binding sites in
ATRA-treated mouse embryonic stem cells revealed that nearly
80% of binding sites have a DR5 or DR2 motif, while 90% have
Figure 1. PML-RARa and RXR Colocalization to Genomic Regions
(A) Overview of the RARb, RUNX1, RARa, and GFI1 PML-RARa/RXR binding sites. In red, the PML ChIP-seq data are plotted; in purple, the RARa data; and in
blue, the RXR data.
(B) PML-RARa and RXR binding sites detected by ChIP-seq in leukemic NB4 cells. PML and RARa peaks were called using MACS (p < 106) after which relative
RARa, PML, and RXR tag density was determined at these peaks. Results were sorted according to relative tag density and the top 8000 peaks were displayed in
a regression curve. A cut off was set at a relative tag density of 0.00012 (14 tags/kb).
(C) Box plot showing the percentage of PML, RARa, and RXR tags, within three groups of PML-RARa binding sites that harbor different RXR densities or a set of
random regions of similar size.
(D) Distribution of the PML-RARa/RXR binding site location relative to ENSEMBL genes (left) compared to the tag distribution of total genomic DNA (right). Loca-
tions of binding sites are divided in 50 far (25 kb to5 kb of the transcription start site), 50 near (5 kb to the transcription start site), gene body (gene), 30 near (end
of untranslated region to +5 kb), 30 far (untranslated region +5 kb to +25 kb), and distant (everything else). See also Figure S1 and Tables S1 and S2.
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PML-RARa-Associated Chromatin Alterationsa DR1–5 motif (unpublished data). Together, these analyses
reveal a gain in DNA binding repertoire for PML-fused RARa as
compared to wild-type RARa.
As many single binding regions contain several consensus
binding sites we counted the total number of DR motifs
(Figure 2C). DR5, DR2, and DR1, the primary targets of RARa/
RXR heterodimers (Mangelsdorf et al., 1995; Castelein et al.,
1996), are the most abundant within our PML-RARa/RXR
binding sites, closely followed by the DR4 and DR8. Although
the DR configuration (Figure 2C, blue and green bars) seems
to be most abundant, still very considerable numbers of inverted
and everted repeats (red bars) are detected, underscoring the
gain of DNA binding capacity of PML-RARa/RXR complexes.CIdentification of PML-RARa/RXR Peaks in APL Blasts
To examine whether the high confidence PML-RARa/RXR peaks
found in NB4 cells are present in primary PML-RARa-expressing
blasts, we performed ChIP-seq for PML and RXR in two samples
from patients with APL harboring the t(15;17) translocation and
expressing the Bcr1 isoform of PML-RARa. We obtained PML-
RARa and RXR peaks at similar genomic regions in primary
APL cells as in NB4, for example, at the cell cycle regulator
HNRNPM and the metalloprotease protein SPG7 genes (Figures
3A and 3B). We counted the PMLAPL tags within the PML-RARa
binding regions identified in the NB4 cell line and plotted the
results in a regression curve (Figure 3C). We could detect signif-
icant levels (>10 tags/kb) of PMLAPL tag densities at 718 bindingancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc. 175
Figure 2. Presence of DR, ER, and IR Motifs
in PML-RARa/RXR Peaks
(A) Overview of the architecture and spacing of
different DR motifs that were used to analyze
PML-RARa binding sites.
(B) Analysis of the presence of DR motifs under-
lying PML-RARa/RXR binding sites. PML-RARa/
RXR binding sequences were searched first for
the presence of DR1–5 motifs, and then for
DR0,6–13 motifs and then for presence of ER or
IR motifs.
(C) Total numbers of the different DR motifs
present in the PML-RARa/RXR binding regions.
DR motifs were counted and ordered according
to the total number.
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PML-RARa-Associated Chromatin Alterationsregions in APL blast 164 and 1868 binding regions in APL blast
74 (Table S3), indicating that PML-RARa is enriched at a subset
of binding regions in the APL blasts as compared to NB4. This is
likely due to lower expression levels of PML-RARa in APL blasts
(Grignani et al., 1993) and to greater heterogeneity of the blast
samples as compared to NB4.
Overlapping the binding regions of NB4 cells with the two blast
samples (Figure 3D) revealed a common set of 600 regions
(Table S3). These regions show a similar distribution of binding
motifs as the binding regions in NB4 (Figure 3E), suggesting
that also in blasts PML-RARa binding is observed beyond the
classical RAR/RXR targets. As these NB4 and APL common
regions might represent the key binding sites for PML-RARa-
induced oncogenic transformation we performed functional
analysis of the associated genes using GO annotation clustering
(Figure S2). This revealed high enrichment scores (>3) for genes
involved in signal transduction and hematopoietic differentiation.
To investigate the colocalization of RXR with PML-RARa in the
APL blast, we performed a regression curve analysis (Figure 3C).
The vast majority of PML-RARaAPL peaks contain high levels of
RXRAPL tags, indicating a highly significant overlap between
PML-RARa and RXR binding in the APL blast corroborating
and extending the colocalization obtained in the NB4 leukemic
cell line.
ATRA Induces Changes in H3 Acetylation
at PML-RARa/RXR Binding Regions
To overcome the transforming potential of PML-RARa, human
APL patients are treated during the early phase of the disease
with pharmacological doses of ATRA (Di Croce, 2005; Licht,
2006). In NB4 cells, ATRA induces differentiation, which is char-
acterized by a change in nuclear morphology and an altered PML
distribution (Figures S3A and S3B), due to the ATRA-induced
degradation of PML-RARa (data not shown; Raelson et al.,
1996). It has been postulated that this ATRA-induced dislodging176 Cancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc.of PML-RARa causes extensive redistri-
bution of epigenetic marks.
Genome-wide analyses showed that
PML, RARa, and RXR are lost following
24 hr ATRA treatment of NB4 cells at
many of the PML-RARa/RXR binding
sites, such as the TGM2, CCL2, and
RNPEPL1 genomic regions (FiguresS3C–S3E). Counting PML, RARa, and RXR tags within all of
the PML-RARa target regions before and after ATRA treatment
revealed a strong decrease toward background levels for all
our high confidence targets (Figure S3F), showing that both
PML-RARa and RXR binding are lost upon ATRA treatment.
To investigate whether and which chromatin modifications are
mediated by PML-RARa, we performed ChIP-seq using anti-
bodies recognizing H3K9K14ac, H3K27me3, and H3K9me3 in
proliferating and ATRA-treated NB4 cells. Moreover, we used
GST-MBD pull-down (MethylCap) followed by deep sequencing
to assess ATRA-induced global changes in DNA methylation.
First we examined these modifications at the HOXA, HOXB,
HOXC, and HOXD genomic regions and noticed that H3 acetyla-
tion appears in sharp narrow peaks at specific genomic loca-
tions, especially in HOXA and HOXC (Figures S3G–S3J). In
accordance with other genome-wide studies in mammalian
cells (Barski et al., 2007; Pan et al., 2007; Zhao et al., 2007),
we found broad enrichment of H3K27me3 over the HOX clusters
and DNA methylation largely restricted to CpG islands (Meissner
et al., 2008).
Next, we examined the RARb promoter and noticed enrich-
ments of H3K27me3 and DNA methylation in untreated NB4 cells
at the PML-RARa/RXR binding site in accordance with pub-
lished results (Villa et al., 2007; Di Croce et al., 2002); however,
it did not change upon ATRA treatment. Strikingly, the main
effect was a very marked increase of H3 acetylation (Figure 4A).
Similarly, at the GALNAC4S, PRAM1, and PRTN3 genes, ATRA
induced a strong increase in H3K9K14ac at PML-RARa/RXR
binding sites (Figures 4B–4D). Quantitation of H3K9K14ac,
H3K27me3, H3K9me3, and DNAme within the PML-RARa/RXR
target regions before and after ATRA treatment confirmed and
extended our observations to the global scale. While
H3K27me3, H3K9me3, and DNAme were low both before and
after ATRA treatment, H3K9K14ac tags were clearly increased
upon ATRA treatment (Figure 4E). This increase in H3K9K14ac
Figure 3. Identification of PML-RARa/RXR Binding Sites in APL Blasts
(A and B) Overview of the HNRNPM and SPG7 PML-RARa/RXR binding sites in NB4 leukemic cells and two patient APL blasts (pz164 and pz74). In red, the PML
ChIP-seq data are plotted and, in blue, the RXR data.
(C) Regression curve analysis of PMLAPL and RXRAPL tags at the PML-RARa/RXR binding sites identified in NB4 cells. A cut-off was set at a relative tag density of
10 tags/kb.
(D) Venn diagram representing the overlap of binding sites detected in NB4 cells and two patient blasts.
(E) Analysis of the presence of DR motifs underlying the overlapping PML-RARa/RXR binding sites from NB4 cells and two patient blasts. See also Figure S2 and
Table S3.
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PML-RARa-Associated Chromatin Alterationswas not dependent on the genomic localization of the binding
site as similar patterns were observed for binding regions in
promoters, coding bodies, and noncoding regions (Figure S3K).
Interestingly, even before ATRA treatment a considerable
amount of H3K9K14ac is detectable at PML-RARa/RXR binding
sites, suggesting that the PML-RARa complex can also bind
DNA templates that do not have a fully hypoacetylated chro-
matin composition.
To substantiate our findings we performed hierarchical clus-
tering using the ATRA-induced changes in H3K9K14ac,
H3K27me3, H3K9me3, and DNAme at each binding region for
PML-RARa/RXR. This allowed us to identify six clusters of
binding sites with typical epigenetic responses to ATRA (Fig-
ure 4F). Four out of six clusters (representing 81% of PML-
RARa/RXR binding regions) display increases in H3 acetylation,
confirming that this mark is closely linked to ATRA-induced loss
of PML-RARa binding. Interestingly, cluster 1 represents PML-
RARa/RXR binding regions that display increases in both
H3K9me3 and H3K9K14ac. Although H3K9me3 has been
described as present at heterochromatic regions (Peters et al.,
2003) it was also found at transcribed genes (Vakoc et al.,
2005; Brinkman et al., 2006; Wiencke et al., 2008). Therefore,
this small cluster might represent a subset of PML-RARa/RXR
binding sites localized in the coding body of ATRA-induced
genes. Clusters 5 and 6 do not display increases in H3 acetyla-
tion, suggesting either that these binding regions already haveCincreased levels of acetylation or that degradation of PML-
RARa alone is not sufficient for these regions to become hyper-
acetylated and that additional factors prohibit the recruitment of
the enzymes responsible for establishing a hyperacetylated
chromatin state. In sharp contrast to the very widespread
increases in H3 acetylation, decreases in H3K27me3 and
DNAme are only observed at 29 binding regions (Table S2).
As PML-RARa binding was observed at various genes encod-
ing chromatin-modifying enzymes (Table S4) such as JMJD3
(H3K27 demethylation), SETDB1 (H3K9 methylation), and
DNMT3a (DNA methylation), we examined whether loss of
PML-RARa results in genome-wide epigenetic alterations. For
this we searched for DNA regions that display at least 3-fold
changes in epigenetic marks. We detected 6911 differentially
acetylated (DAR), 10295 differentially K27 methylated (DK27R),
6132 differentially K9 methylated (DK9R), and 1625 differentially
DNA methylated (DMR) regions (Table S5 and Figure S3L).
Of the genomic regions that display an increase in H3 acetyla-
tion, 511 overlapped with PML-RARa/RXR binding sites,
whereas only 15 of the differentially K27 methylated and DNA
methylated regions showed an overlap with PML-RARa/RXR
peaks (Figure S3M). Together these results show that NB4
differentiation is characterized by extensive genome-wide
epigenetic changes but also reemphasize the intimate connec-
tion between PML-RARa/RXR binding and the regulation of H3
acetylation levels.ancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc. 177
Figure 4. ATRA-Induced Epigenetic Changes at PML-RARa/RXR Binding Regions in NB4 Cells
(A–D) Overview of theRARb,GALNAC45, PRAM1, and PRTN3 PML-RARa/RXR binding site in NB4 cells. In red the PML, in purple the RARa, and in blue the RXR
ChIP-seq data are plotted for proliferating NB4 cells. For H3K9K14ac (pink), H3K27me3 (yellow), H3K9me3 (green), and DNAme (turquoise), the data are plotted
both for proliferating and for 24 hr (H3K9K14ac, H3K27me3, and H3K9me3) or 48 hr (DNAme) ATRA-treated NB4 cells.
(E) Box plot showing the percentage of H3K9K14ac, H3K27me3, H3K9me3, and DNAme tags, before and after ATRA treatment of NB4 cells, within all PML-
RARa/RXR peaks.
(F) Clustering analysis of epigenetic changes at PML-RARa/RXR peaks. Log2 values for ATRA-induced changes in H3K9K14ac, H3K27me3, H3K9me3, and
DNAme for each binding site were calculated and used for hierarchical clustering. Depicted below each cluster is the number of peaks within the cluster and
the directionality (increase, no change, or decrease) for each epigenetic modification. See also Figure S3 and Tables S4 and S5.
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PML-RARa-Associated Chromatin AlterationsIncreases in H3 Acetylation Are Only Observed
in ATRA-Responsive Leukemic Cells
To corroborate the relation between PML-RARa and H3 acetyla-
tion, we performed ChIP-seq experiments in the ATRA-resistant
subclone NB4-MR4 (Rosenauer et al., 1996). NB4-MR4 contains
a mutation in PML-RARa that strongly reduces its affinity for
ATRA, while it does not affect its ability to bind DNA and block
transcription (Shao et al., 1997). Genome-wide profiling of PML
and H3K9K14ac in this cell line revealed that PML-RARa binding
is not lost after ATRA treatment at the CCL2, NINJ2, and PRAM1
genes (Figures S3N–S3P) and that changes in H3K9K14ac were
marginal. Examining all our high confidence PML-RARa binding
sites revealed that PML-RARa binding is not lost and importantly
that the vast majority of regions (2084) did not show alterations in
H3K9K14ac upon ATRA treatment (Figure S3Q), while 188
showed decreased and 450 increased H3K9K14ac levels.
Importantly, the subset of binding regions that displayed
ATRA-increased H3K9K14ac is significantly less acetylated in178 Cancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc.NB4-MR4 than in NB4 cells (p = 4.8 3 1012), suggesting that
these targets became partially (de)acetylated independent
from PML-RARa/RXR.
Decreased Acetylation upon Induced PML-RARa/RXR
Binding
To even further substantiate the intimate link between PML-
RARa binding and H3 deacetylation we performed ChIP-seq
experiments in the PML-RARa zinc-inducible cell line U937,
UPR9 (Grignani et al., 1993). Genome-wide profiling of PML
and RARa before zinc induction revealed a small number of
binding regions. Importantly, these regions did not represent
individual PML and RARa binding sites but showed significant
overlap (e.g., UNC458 in Figure S4A), suggesting leakage of
PML-RARa expression. Numerous new binding sites could be
detected following 5 hr zinc induction such as at the RARa,
ICAM1, and PARP2 genes (Figures S4B–S4D). In accordance
with the observed colocalization in NB4 and APL blasts,
Figure 5. Reduced H3 Acetylation upon
PML-RARa Binding
(A–C) Overview of the PRAM1, PIK3AP1, and
TNNI2 binding regions in untreated (zinc) and 5
hr zinc-treated (+zinc) UPR9 cells. In red, the
PML; in purple, the RARa; in blue, the RXR; in
pink, the H3K9K14ac; and in yellow, the
H3K27me3 ChIP-seq data are plotted.
(D) Box plot showing the average percentage of
PML-RARa tags, before and after zinc treatment
of UPR9 cells, within all PML-RARa/RXR peaks
detected after zinc treatment (left) and the 50%
of peaks that show the highest level of PML-
RARa induction (right).
(E) Box plot showing the percentage of
H3K9K14ac and H3K27me3 tags, before and after
zinc treatment of UPR9 cells, within all PML-
RARa/RXR peaks detected after zinc treatment
(left) and the 50% of peaks that show the highest
level of PML-RARa induction (right). See also
Figure S4.
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PML-RARa-Associated Chromatin AlterationsPML-RARa binding resulted in co-recruitment of RXR also in the
UPR9 cell line (Figures S4E and S4F). Only a very low number of
RXR binding sites were detected in untreated UPR9 cells, while
in zinc-treated UPR9 cells the increase in RXR binding sites was
proportional to the increase in PML-RARa binding sites. Thus
RXR binding appears to be dependent on PML-RARa.
In total we identified 94 and 5632 PML-RARa/RXR binding
sites in untreated and treated UPR9 cells, respectively. As
zinc-induced UPR9 cells express significantly higher levels of
PML-RARa than NB4 cells (Grignani et al., 1993), these findings
indicate that the number of PML-RARa/RXR binding sites corre-
lates with its expression level. Interestingly, the binding sites
identified in UPR9 cells only partially overlapped with those in
NB4 and APL cells (Figures S4G and S4H), suggesting that this
model system does not fully recapitulate NB4 and APL.
Genome-wide profiling of H3K9K14ac and H3K27me3 re-
vealed decreased acetylation at many of the 5 hr zinc-induced
PML-RARa/RXR binding sites, such as those found at theCancer Cell 17, 173–185,PRAM1, PIK3AP1, and TNNI2 genes
(Figures 5A–5C), while changes in
H3K27me3 were not observed. To
substantiate these findings we counted
the number of PML-RARa, H3K9K14ac,
and H3K27me3 tags within all the UPR9
PML-RARa/RXR target regions before
and after zinc treatment. Although the
kinetics of histone deacetylation is 2-
fold lower than histone acetylation (Sun
et al., 2003) and the treatment period is
significantly shorter (i.e., 5 hr in UPR9
versus 24 hr ATRA in NB4), a very signif-
icant (p = 4.5 3 1018) decrease in H3
acetylation levels (Figures 5D and 5E,
left) was observed. To investigate
whether the decrease in H3 acetylation
correlates with increased PML-RARa
binding we also examined H3K9K14ac
and H3K27me3 at the 50% most inducedUPR9 PML-RARa binding regions (Figure 5D, right). This re-
vealed an even more significant decrease (p = 1.7 3 1026) in
H3 acetylation levels (Figure 5E, right).
Epigenetic Alteration in Primary APL Blast Cells
Next we investigated whether primary blasts from APL patients
present a similar ATRA-induced effect for H3K9K14ac as the
NB4 cells. For this we performed H3K9K14ac and H3K27me3
ChIP-seq in untreated and ATRA-treated APL (pz164) blasts.
We observed ATRA-induced increases in H3 acetylation at
many of the PML-RARa/RXR binding sites that were detected
in the APL blast, for example, at the CYCLIN D3, RNPEPL1,
and NADK genes (Figures 6A–6C). In contrast, H3K27me3
enrichments were readily detected at the HOX clusters (Figures
S5A–S5D), but barely present at the PML-RARa/RXR binding
regions; the number of H3K9K14ac tags was clearly increased
after ATRA treatment, while changes in H3K27me3 were not de-
tected (Figure 6D). A heat map display of H3 acetylation andFebruary 17, 2010 ª2010 Elsevier Inc. 179
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PML-RARa-Associated Chromatin AlterationsH3K27me3 changes confirmed that the vast majority of PML-
RARa/RXR binding sites (63.6%) show increases in H3 acetyla-
tion (Figure 6E) whereas merely 4.2% show a decrease in H3
acetylation. Again H3K27me3 changes could hardly be de-
tected, reemphasizing that ATRA-induced PML-RARa degrada-
tion is linked with increased H3 acetylation.
ATRA-Induced Changes in RNAPII Occupancy Correlate
with H3 Acetylation Levels at Nearby PML-RARa/RXR
Peaks
To extend our study we performed ChIP-seq using an antibody
against RNA polymerase II (RNAPII) in proliferating and 24 and
48 hr ATRA-treated NB4 cells. RNAPII occupancy throughout
the gene body provides a very good readout of transcriptional
activation or repression and thus yields insights beyond what
is typically obtained by mRNA expression profiling (Nielsen
et al., 2008; Welboren et al., 2009). For example, at the TGM2
gene, a known PML-RARa target, we see an increase in RNAPII
tags over the gene body both after 24 and 48 hr ATRA treatment
(Figure 7A). This increase is also evident at many other genes
such as the ASB2, CCL2, DHRS3, and LRG1 genes (Figures
S6A–S6D).
We calculated the relative difference in number of tags per
kilobase for each ENSEMBLE gene between different time
points and applied a threshold for selection of ATRA-regulated
genes at ±1.5 standard deviation of the log2 ratio (Figure S6E).
Among the ones that show the highest increase in RNAPII occu-
pancy are classical ATRA targets such as CCL2, G0S2, and
ICAM1 (Table S6). Globally we identified 1054 genes with
increased and 946 genes with lowered RNAPII occupancies after
ATRA treatment (Table S6). A subset of these genes were
selected and confirmed by RT-qPCR, validating the use of RNA-
PII occupancy as readout of transcriptional activity (Figures S6F
and S6G).
To correlate transcription with PML-RARa/RXR peaks we
identified all ATRA-induced and -repressed genes that have at
least one PML-RARa/RXR peak at the coding region, within
25 kb upstream of the transcription start site or 25 kb down-
stream of the 30 untranslated region of the gene. This led to the
identification of 154 ATRA-induced genes and 258 ATRA-
repressed genes that have a nearby PML-RARa/RXR binding
region. Functional classification of these genes showed that
induced genes are mainly associated with development, differ-
entiation, and signal transduction, while repressed genes have
functions associated with cell metabolism (Figure S6H), prob-
ably as a consequence of the ATRA-induced proliferation stop.
Next we counted the H3K9K14ac, H3K27me3, H3K9me3, and
DNAme tags at the PML-RARa/RXR binding region (peak) and at
the gene body (gene) of the ATRA-induced and -repressed
genes. Strikingly, PML-RARa/RXR binding regions associated
with induced genes display on average low levels of H3 acetyla-
tion before induction that are clearly increased after ATRA
treatment (Figure 7B). In contrast, ATRA-repressed genes
show significant levels of H3 acetylation before induction and
display only limited increases of this mark. Similar differences
in H3K9K14ac are obtained between ATRA-induced and
-repressed genes at the gene body (Figure 7C). The levels of
H3K27me3, H3K9me3, and DNAme are generally very low at
PML-RARa/RXR peaks. Strikingly, DNAme is clearly elevated180 Cancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc.at the gene bodies of induced genes in accordance with previous
studies (Zhang et al., 2006; Zilberman et al., 2007), while
elevated H3K9me3 at gene bodies correlates with increased
transcriptional activity.
These findings are corroborated and extended when exam-
ining differentially acetylated, H3K27 methylated, H3K9 methyl-
ated, and DNAme regions at peak and gene body regions of
induced or repressed genes. Only differentially acetylated
regions significantly colocalize with peaks and gene bodies of
induced genes (91 and 157, respectively) while only few are
present at repressed genes (Figures 7D and 7E). Increased
H3K9me3 is again linked to ATRA-induced genes. These find-
ings show that ATRA-induced genes have a higher increase of
H3 acetylation as compared to ATRA-repressed genes and
suggest that the gain in H3 acetylation at PML-RARa/RXR
binding regions correlates with the nearby gene expression.DISCUSSION
Since its discovery in 1990, PML-RARa had been the paradigm
oncofusion protein for understanding the molecular aspects
of oncogenesis. Throughout the years many mechanisms
have been proposed for PML-RARa function, including homodi-
merization, oligomerization, interaction with RXR, expanded
DNA binding affinity, and recruitment of a wide spectrum of
epigenetic enzymes. Most, if not all, of these mechanisms
have been based on in vitro studies, overexpression of PML-
RARa in model cell systems, and small scale ChIP and ChIP-
chip experiments centered on the best known PML-RARa target:
the RARb promoter. Although RARb is a target, it may not be
representative of the entire repertoire of PML-RARa targets
and actions.
Here we have identified 2722 binding sites to which both PML
and RARa bind with high confidence. As wild-type PML is ex-
pected to colocalize with RARa in APL cells, these findings,
together with our PML/RARa double ChIP analysis and the
observation that ATRA induces reduced PML and RARa occu-
pancies, strongly suggest that these high-confidence binding
sites represent bona fide PML-RARa targets.
Analyses of these targets suggest that PML-RARa induces
oncogenic transformation at multiple levels. We found that
PML-RARa influences RAR signaling by regulating RARa and
RARb expression and binding to the presumed classical RAR/
RXR genomic targets (sites containing DR1, DR2, and DR5).
Moreover, we detected PML-RARa binding at genes important
for normal hematopoietic differentiation, such as SPI1, GFI1,
and RUNX1 and, in addition, at genes that can alter chromatin,
suggesting PML-RARa control at the epigenetic level.
Our in vivo binding studies unambiguously reveal RXR as
a binding partner of PML-RARa at a global scale, essentially at
all binding sites. Analysis of these binding sites showed that,
as for the RARa/RXR heterodimer, the PML-RARa/RXR complex
targets DNA regions containing a DR1, DR2, or DR5 motif. Our
in vivo analysis also revealed that PML-RARa/RXR binding is
extended to DNA regions that have DR motifs with different
spacing (between 0 and 13) and architecture (direct, inverted,
or everted repeat) in line with previous reported in vitro data
(Kamashev et al., 2004). This broadened spectrum of genomic
Figure 6. ATRA-Induced Acetylation Changes at PML-RARa/RXR Binding Regions in NB4 and APL (pz164) Blast Cells
(A–C) Overview of theCCND3,RNPEPL1, andNADKPML-RARa/RXR binding sites in NB4 leukemic cells (top) or a patient APL blast (bottom). In red the PML and
in blue the RXR ChIP-seq data are plotted for untreated NB4 and patient APL cells. For H3K9K14ac (pink) and H3K27me3 (yellow) the data are plotted both for
proliferating and for ATRA-treated cells.
(D) Box plot showing the percentage of H3K9K14ac and H3K27me3 tags, before and after ATRA treatment of patient APL cells, within all PML-RARa/RXRAPL
peaks.
(E) Heat map displaying Log2 values for ATRA-induced changes in H3K9K14ac and H3K27me3 for each PML-RARa/RXR binding site identified in patient APL
cells. See also Figure S5.
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PML-RARa-Associated Chromatin Alterationsregions regulated by PML-RARa/RXR is probably due to its olig-
omerization properties and likely contributes significantly to the
oncogenic action of the fusion protein.CIn addition to the APL-derived cell line NB4 we performed
ChIP-seq analysis to verify PML-RARa/RXR binding regions in
primary blasts from two patients with newly diagnosed APL.ancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc. 181
Figure 7. ATRA-Induced Transcriptional Changes Correlate with H3 Acetylation Changes at PML-RARa/RXR Binding Regions
(A) Overview of ATRA-induced expression of the TGM2 gene. In red the PML, in purple the RARa, and in blue the RXR ChIP-seq data are plotted for proliferating
NB4 cells. In green the RNAPII data are plotted for proliferating and 24 or 48 hr ATRA-treated NB4 cells. For H3K9K14ac (pink), H3K27me3 (yellow), H3K9me3
(green), and DNAme (turquoise) the data are plotted both for proliferating and for 24 hr (H3K9K14ac and H3K27me3) or 48 hr (DNAme) ATRA-treated NB4 cells.
(B and C) Box plot showing the percentage of H3K9K14ac, H3K27me3, H3K9me3, and DNAme tags, before and after ATRA treatment of NB4 cells, within PML-
RARa/RXR peaks (B) or gene bodies (C) of ATRA-induced or -repressed genes.
(D) Total numbers of increased or decreased acetylated (DAR), lysine 27 methylated (DK27R), lysine 9 methylated (DK9R), and DNA methylated (DMR) regions
detected at PML-RARa/RXR peaks associated with ATRA-induced or -repressed genes.
(E) Total numbers of differentially acetylated, lysine 27 methylated, lysine 9 methylated, and DNA methylated regions detected at ATRA-induced or -repressed
genes that harbor a nearby PML-RARa/RXR binding site. See also Figure S6 and Table S6.
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PML-RARa-Associated Chromatin AlterationsThe higher heterogeneity of the APL blasts in respect to the NB4
cell line and the lower expression levels of PML-RARa let us only
validate a subset of binding sites. As for the PML-RARa binding
sites identified in the leukemic NB4 cells, the vast majority of
PML-RARa binding regions identified in the APL blasts display
very significant RXR enrichment, corroborating that PML-RARa
complexes colocalize with RXR in primary patients’ cells and
further endorsing the therapeutic potentials of RXR agonists in
the treatment of APL.
Pharmacological doses of ATRA induce large-scale epige-
netic changes in the NB4 leukemic cell line, with thousands of
regions displaying alteration in H3 acetylation, H3K27 methyla-
tion, H3K9 methylation, and DNAme. Most PML-RARa/RXR
binding sites display a greater than 2- to 3-fold increase in
histone acetylation levels, a finding that could be corroborated
and extended to PML-RARa/RXR binding sites in an APL blast.
In contrast, alterations in H3K27 methylation, H3K9 methylation,
and DNAme are associated with only a minute number of PML-
RARa/RXR binding sites, suggesting that the global changes in
these repressive marks are triggered by altered PML-RARa/
RXR occupancy at a subset of chromatin-modifying genes and
by differentiation rather than by release of chromatin-modifying
enzymes from the PML-RARa/RXR complex itself. While PML-
RARa degradation in NB4 cells results in increased H3 acetyla-
tion at PML-RARa/RXR binding sites we could show that induc-
tion of PML-RARa expression in UPR9 cells and gain of binding
results in lower levels of H3 acetylation. Together these results
suggest that regulation of local H3 acetylation levels is the
most important enzymatic property directly associated with the
PML-RARa/RXR complex, although further functional studies
are needed to investigate the importance of histone deacetyla-
tion in the transformation process over other epigenetic marks.
We performed genome-wide profiling of RNAPII occupancy
and defined nearly 2000 ATRA upregulated or downregulated
genes. Our analysis confirmed and extended several mRNA mi-
croarray studies that have previously been performed on ATRA-
treated NB4 cells (Lee et al., 2002; Yang et al., 2003; Wang et al.,
2004; Meani et al., 2005). To our surprise only 10% of both the
upregulated as the downregulated genes in all these studies
were proximal to PML-RARa/RXR peaks, while the majority of
ATRA-affected genes were localized at greater distance from
these binding sites. For the proximal genes, we observed clear
differences in chromatin alterations between ATRA-induced
and -repressed genes, with ATRA-induced genes displaying
very significantly increased levels of H3 acetylation. Interest-
ingly, genes proximal to PML-RARa/RXR peaks that are induced
upon ATRA treatment are mainly associated with development
and signal transduction, while repressed genes proximal to
PML-RARa/RXR peaks have functions associated with cell
metabolism and might represent a group of targets indirectly
regulated by the onset of the ATRA-induced differentiation
program.
Unlike genetic mutations, epigenetic alterations can be reacti-
vated to force cells into differentiation, apoptosis, or senes-
cence. This plasticity makes epigenetic modifications ideal
targets for therapeutic intervention in cancer. Therapeutic
agents aimed at reactivating silenced genes have already been
successfully used in treatment of acute myeloid leukemias that
harbor other genetic mutations than t(15;17) (Marks, 2004; Neb-Cbioso et al., 2005; Yoo and Jones, 2006) or to reverse gene
repression in breast cancer (Tan et al., 2007). Our results unam-
biguously show that at the molecular level regulation of H3 acet-
ylation is tightly linked to PML-RARa transformation, endorsing
the therapeutic potential of HDAC inhibitors in APL. In conjunc-
tion with components that target the transforming PML-RARa/
RXR complex itself, like ATRA (Quignon et al., 1997), As2O3
(Zhu et al., 2001), RXR agonists (Benoit et al., 1999), and cAMP
(Nasr et al., 2008), inhibition of HDACs thereby provides an addi-
tional level to therapeutically eradicate these cancer cells.
EXPERIMENTAL PROCEDURES
ChIP
NB4 cells were routinely cultured in RPMI supplemented with 10% FCS at
37C and, when indicated, treated for 24 or 48 hr with 1 mM ATRA. Chromatin
was harvested as described (Denissov et al., 2007). ChIPs were performed
using specific antibodies to PML, RXR (Santa Cruz), RNAPII, H3K9K14ac,
RARa (Diagenode), H3K9me3, and H3K27me3 (Peters et al., 2003) and
analyzed by quantitative PCR (qPCR). Primers for qPCR are described in
Supplemental Information. Relative occupancy was calculated as fold over
background, for which the second exon of the Myoglobin gene was used.
Illumina High-Throughput Sequencing
End repair was performed using the precipitated DNA of 6 million cells (three
to four pooled biological replicas) using Klenow and T4 PNK. A 30 protruding A
base was generated using Taq polymerase and adapters were ligated. The
DNA was loaded on gel and a band corresponding to 200 bp (ChIP fragment
+ adapters) was excised. The DNA was isolated, amplified by PCR, and used
for cluster generation on the Illumina 1G genome analyzer. The 32 bp tags were
mapped to the human genome HG18 using the eland program allowing one
mismatch. The 32 bp sequence reads were directionally extended to
133 bp, corresponding to the length of the original fragments used for
sequencing. For each base pair in the genome the number of overlapping
sequence reads was determined and averaged over a 10 bp window and visu-
alized in the University of California Santa Cruz genome browser (http://
genome.ucsc.edu). For biological replicates, the number of uniquely mapped
32 bp tags was normalized between the two samples. The normalized number
of tags was pooled and the resulting file was used for identification of binding
sites. A list of the ChIP-seq profiles analyzed in this study can be found in
Supplemental Information. All ChIP-seq data can be downloaded from Gene
Expression Omnibus under accession number GSE18886.
Peak Detection and Motif Search
PML and RARa peaks were detected using MACS (Zhang et al., 2008). Result-
ing peak regions were tested for relative PML, RARa, and RXR tag density (tag
density at peak divided by total number of tags at all peaks), sorted, and visu-
alized in a dot plot using regression analysis. To identify the DR motifs under-
lying the PML-RARa peaks, the Possum software available at the MotifViz
webserver was used (Fu et al., 2004) together with a file containing matrices
for different DR motifs.
MethylCap
Pull-down experiments were performed using GST fused to the MBD domain
of MeCP2 (Diagenode). DNA was isolated from proliferating and ATRA-treated
NB4 cells, sonicated to generate fragments of 400 bp, and pulled down with
GST-MBD-coated paramagnetic beads and the IP-STAR robot (Diagenode).
After washing with 200 mM NaCl, the bound methylated DNA was eluted using
700 mM NaCl and used for high-throughput DNA sequencing (A.B.B. and
H.G.S., unpublished data).
RNAPII Analysis
Quantitation of RNAPII occupancy changes was done as described previously
(Nielsen et al., 2008; Welboren et al., 2009) and total gene expression change
was analyzed by averaging the log2 ratios of the comparison 24 and 48 hr
ATRA treated with proliferating NB4 cells. A threshold for selection ofancer Cell 17, 173–185, February 17, 2010 ª2010 Elsevier Inc. 183
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PML-RARa-Associated Chromatin AlterationsATRA-regulated genes was set at ±1.5 standard deviation and a subset of
genes was validated by quantitative reverse transcriptase PCR. Functional
classification of genes was performed using PANTHER and GO clustering at
DAVID bioinformatics resources (http://david.abcc.ncifcrf.gov/).
Differentially Acetylated, Lysine Methylated, and DNA Methylated
Regions
Regions of overlapping tags were extracted from the genome-wide profiles of
H3K9K14ac, H3K27me3, H3K9me3, and DNAme in NB4 cells treated and
untreated with ATRA using an false discovery rate of 106. For each epigenetic
mark the peak files from ATRA and proliferating NB4 cells were combined and
the number of tags within each region was counted before and after ATRA
treatment. Regions displaying over 3-fold increased or decreased numbers
of tags were defined as differentially acetylated, lysine 27 methylated, lysine
9 methylated, or DNA methylated regions.
Patients’ Blasts
Leukemic blasts were obtained from patients with newly diagnosed APL and
t(15;17) after written consent. The samples consisted of more than 80%
bone marrow invasion and were typical FAB M3 expressing the bcr1 PML-
RARa variant. Blasts have been purified as previously reported (Nebbioso
et al., 2005). These studies were approved by the Seconda Universita` degli
Studi di Napoli Ethical Committee (7028032003).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2009.12.042.
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